Mergers and Acquisitions Mergers and Acquisitions Boom in the Pharmaceutical Industry
Merger and acquisitions in the pharmaceutical industry have increased by 26.1 percent, compared to the rather mixed development of 2012. More than $ 141 billion were spend on company acquisitions last year...
After M&A activities fell sharply during 2012, the pharmaceutical branch looks more confidently into the future: Although investments gave in slightly towards the end of 2012, they were still significantly above 2012's values, recent Mergermarket figures show. The highest valued deal so far was the $ 15 billion acquisition of Life Technologies by Thermo Fisher - a transaction tat should significantly increase Thermo's market shares in Asia.
The majority of mergers and acquisitions were witnessed once again in the US (57.7 percent or US $ 81 billion), yet this share was the lowest since 2012. Asian companies meanwhile are increasingly growing by acquisition, though still mostly in their domestic markets. With US $ 4.2 billion, M&A activities in China are a major driving force behind the US $ 12.6 billion merger bill of all Asia. Europe's pharma and biotech market expanded to US 43.8 billion in 2012, in part through incoming deals.